Updates are available Correction dated 2024-03-28
Click to view Correction: https://doi.org/10.1186/s12014-024-09471-y
-
Authors
RamÃrez Medina, Carlos R.
Ali, Ibrahim
Baricevic-Jones, Ivona
Odudu, Aghogho
Saleem, Moin A.
Whetton, Anthony D.
Kalra, Philip A.
Geifman, Nophar
-
Funding
Funding for this research was provided by:
Medical Research Council (MR/R013942/1, MR/R013942/1, MR/R013942/1, MR/R013942/1, MR/R013942/1, MR/R013942/1, MR/R013942/1)
- License Information
-
More Information
Article History
Received: 13 October 2022
Accepted: 14 March 2023
First Online: 20 April 2023
Change Date: 28 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12014-024-09471-y
Declarations
:
: All consents obtained prior to publication.
: Prof. Kalra received speaker and/or advisory board fees from Astra Zeneca, Napp, Bayer, GSK, Boehringer Ingelheim, Vifor, Pharmacosmos, Novonordisk. Prof. Saleem performs consultancy work for: Travere; Confo therapeutics; Purespring Therapeutics. All other authors report no competing interests regarding this manuscript.
